{
    "clinical_study": {
        "@rank": "23196", 
        "acronym": "IDP-118", 
        "arm_group": [
            {
                "arm_group_label": "IDP-118 Low Strength", 
                "arm_group_type": "Experimental", 
                "description": "IDP-118 Low Strength"
            }, 
            {
                "arm_group_label": "IDP-118 High Strength", 
                "arm_group_type": "Experimental", 
                "description": "IDP-118 High Strength"
            }
        ], 
        "brief_summary": {
            "textblock": "Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area\n      affected will be enrolled in the study."
        }, 
        "brief_title": "A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Approximately 60 subjects with a clinical diagnosis of moderate or severe psoriasis (defined\n      as at least of 10 % - 20% treatable Body Surface Area (BSA) and an Investigator's Global\n      Evaluation (IGE) of 3 or 4 at baseline (moderate or severe) will be enrolled in the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female of any race, 18 to 65 (inclusive) years of age.\n\n          -  Freely given verbal and written informed consent obtained from the subject.\n\n          -  Clinical diagnosis of psoriasis at the Screening and Baseline visits with\n\n          -  At least 10% - 20% of  total treatable BSA involvement, and\n\n          -  an Investigator's Global Evaluation score of 3 or 4 ( moderate or severe) on a scale\n             of 0 to 5\n\n          -  Good general health as determined by the Investigator based on the subject's medical\n             history and physical examination, with Screening hematology, serum chemistry, and\n             urinalysis laboratory values within normal range limits.\n\n        Exclusion Criteria:\n\n          -  Presence of psoriasis that was previously treated with prescription medication prior\n             to the Screening visit and is non-responsive to corticosteroid treatment, as\n             determined by the Investigator.\n\n          -  Presence of any concurrent skin condition that could interfere with the evaluation of\n             the study drug, as determined by the Investigator.\n\n          -  History of adrenal disease\n\n          -  Female who is pregnant, nursing an infant, or planning a pregnancy during the study\n             period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670513", 
            "org_study_id": "DPSI-IDP-118-P2-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "IDP-118 Low Strength", 
                "description": "8 weeks", 
                "intervention_name": "IDP-118 Low Strength", 
                "intervention_type": "Drug", 
                "other_name": "IDP-118"
            }, 
            {
                "arm_group_label": "IDP-118 High Strength", 
                "description": "8 weeks", 
                "intervention_name": "IDP-118 High Strength", 
                "intervention_type": "Drug", 
                "other_name": "IDP-118"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Psoriasis", 
        "lastchanged_date": "April 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Rosa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95403"
                    }, 
                    "name": "Dow Clinical Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clinton Township", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48038"
                    }, 
                    "name": "Dow Clinical Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Gratiot", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48059"
                    }, 
                    "name": "Dow Cliincal Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Dow Clinical Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "Dow Clinical Study Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "Dow Clinical Study Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118", 
        "other_outcome": {
            "description": "The Investigator will assess the target lesion site affected by psoriasis at each visit. Areas affected by psoriasis (at a minimum 10% BSA) are to be treated with study drug", 
            "measure": "To evaluate efficacy, defined as reduction of severity of disease in a sample target plaque during the course of the study", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": {
            "affiliation": "Medical Monitor", 
            "last_name": "Todd Plott, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To measure the incidence of HPA axis suppression after treatment with investigational drug product and the comparators", 
            "measure": "The incidence of HPA axis suppression after treatment with investigational drug product and the comparators", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670513"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate and Local Skin Reactions: Tolerability will be evaluated through assessment of selected local signs and symptoms at the drug-application site: itching, dryness, burning and stinging. In addition the treatment areas will be examined at each visit for significant known drug-related AEs such as skin atrophy, striae, telangiectasia and folliculitis.", 
            "measure": "To evaluate the safety and cutaneous tolerability of the two formulations and the comparators", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "Dow Pharmaceutical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dow Pharmaceutical Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}